Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
ACRS - Aclaris Therapeutics, Inc.
Market Cap 684.88M P/E - EPS this Y 53.50% Ern Qtrly Grth -
Income -58.68M Forward P/E -5.21 EPS next Y -8.50% 50D Avg Chg -1.00%
Sales 32.02M PEG -0.03 EPS past 5Y - 200D Avg Chg -21.00%
Dividend N/A Price/Book 3.68 EPS next 5Y 74.40% 52W High Chg -49.00%
Recommedations 3.00 Quick Ratio 7.11 Shares Outstanding 71.34M 52W Low Chg 68.00%
Insider Own 2.64% ROA -25.96% Shares Float 55.21M Beta 0.22
Inst Own 77.67% ROE -37.43% Shares Shorted/Prior 1.71M/1.80M Price 9.69
Gross Margin -173.29% Profit Margin -183.29% Avg. Volume 602,043 Target Price 1.55
Oper. Margin -457.48% Earnings Date Nov 4 Volume 227,498 Change -1.22%
Healthcare | Diagnostics & Research | United States
About Aclaris Therapeutics, Inc.

Aclaris Therapeutics, Inc. a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment provides laboratory services. It develops Zunsemetinib (ATI-450), an MK2 inhibitor which is under Phase 1b/2 trials for the treatment of metastatic breast and pancreatic cancer; ATI-1777, a soft JAK 1/3 inhibitor, completed Phase 2b trails for the treatment of moderate to severe atopic dermatitis and other dermatologic conditions; and ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor under Phase 1 trials as a treatment for T cell-mediated autoimmune diseases. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.

Aclaris Therapeutics, Inc. News
12/03/24 Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
11/26/24 Aclaris Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference
11/21/24 Aclaris Therapeutics And 2 Other US Penny Stocks To Watch
11/20/24 Aclaris Therapeutics upgraded to Buy from Hold at Jefferies
11/19/24 Aclaris Therapeutics upgraded to Buy from Neutral at BTIG
11/19/24 Aclaris Stock Soars As Analysts See Fresh Momentum After Strategic Review And Encouraging Promising Pipeline Developments
11/19/24 Aclaris Therapeutics secures global rights to Biosion’s antibodies
11/19/24 ACRS Stock Up on Licensing Deal With Biosion for Two Immunology Drugs
11/18/24 Biosion Announces Exclusive, Global License Agreement with Aclaris Therapeutics on two potential First-in-Class and Best-in-Class Immunology Assets
11/18/24 Aclaris Therapeutics Announces Exclusive, Global License Agreement with Biosion, Inc., adding Potential Best-in-Class Biologics Assets to Pipeline
11/18/24 Aclaris Therapeutics Announces $80 Million Private Placement
11/12/24 News Flash: Analysts Just Made A Meaningful Upgrade To Their Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Forecasts
11/09/24 Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates
11/06/24 Aclaris Therapeutics (ACRS) Reports Q3 Loss, Misses Revenue Estimates
11/06/24 Aclaris: Q3 Earnings Snapshot
11/06/24 Aclaris Therapeutics Reports Third Quarter 2024 Financial Results and Provides a Corporate Update
10/23/24 Discovering Penny Stocks On US Exchanges: 3 Picks Under $100M Market Cap
10/09/24 Millennium Management LLC Reduces Stake in Aclaris Therapeutics Inc
10/08/24 Is BellRing Brands (BRBR) Stock Outpacing Its Medical Peers This Year?
09/18/24 Aclaris doses first subject in Phase IIa atopic dermatitis treatment trial
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Monahan Joseph Chief Scientific Off.. Chief Scientific Officer Oct 23 Sell 5.0767 6,000 30,460 129,724 10/25/23
Manion Douglas J. Pres and CEO Pres and CEO Mar 09 Buy 7.735 6,500 50,278 6,500 03/09/23
Walker Neal Director Director Mar 01 Sell 12.5 59,240 740,500 1,273,202 03/03/23
Monahan Joseph Chief Scientific Off.. Chief Scientific Officer Mar 01 Sell 12.5 30,837 385,462 147,724 03/03/23
Balthaser Kevin Chief Financial Offi.. Chief Financial Officer Mar 01 Sell 12.46 1,894 23,599 5,256 03/03/23
SCHIFF ANDREW N Director Director Nov 10 Sell 17.05 53,926 919,438 434,455 11/14/22
SCHIFF ANDREW N Director Director Oct 04 Sell 16.27 45,539 740,920 588,916 10/06/22
SCHIFF ANDREW N Director Director Jun 17 Sell 15.1428 19,565 296,269 06/21/22
Walker Neal President and CEO President and CEO Apr 21 Sell 15.15 70,000 1,060,500 1,245,763 04/25/22
Monahan Joseph Chief Scientific Off.. Chief Scientific Officer Apr 18 Sell 16.2766 30,000 488,298 106,386 04/20/22
Walker Neal President and CEO President and CEO Mar 11 Sell 15.9147 56,303 896,045 1,315,763 03/14/22
Ruffo Frank Chief Financial Offi.. Chief Financial Officer Mar 10 Sell 15.5451 12,823 199,335 201,883 03/14/22
Gordon David N. Chief Medical Office.. Chief Medical Officer Jun 02 Sell 22.51 51,914 1,168,584 144,078 06/02/21
Ali-Jackson Kamil Chief Legal Officer Chief Legal Officer Jun 02 Sell 22.32 45,119 1,007,056 131,688 06/02/21
Monahan Joseph Chief Scientific Off.. Chief Scientific Officer Jun 02 Sell 21.91 21,790 477,419 85,342 06/02/21
Ruffo Frank Chief Financial Offi.. Chief Financial Officer Jun 02 Sell 21.91 15,037 329,461 169,872 06/02/21
Walker Neal President and CEO President and CEO Jun 02 Sell 21.9 33,260 728,394 1,232,182 06/02/21
Ali-Jackson Kamil Chief Legal Officer Chief Legal Officer May 07 Option 10.66 20,416 217,635 149,034 05/07/21
Ali-Jackson Kamil Chief Legal Officer Chief Legal Officer May 07 Sell 23.6 20,416 481,818 143,618 05/07/21
Ruffo Frank Chief Financial Offi.. Chief Financial Officer Apr 26 Sell 26.61 87,339 2,324,091 151,720 04/26/21
Mehra Anand Director Director Feb 03 Option 18.34 14,632 268,351 30,841 02/03/21